Zenas BioPharma (ZBIO) Share-based Compensation (2023 - 2026)

Zenas BioPharma's Share-based Compensation history runs 4 years deep, the most recent figure standing at $9.2 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 70.72% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $30.2 million (up 97.61% YoY), while the FY2025 annual figure was $26.3 million, up 143.48% from the prior year.
• Share-based Compensation was $9.2 million for Q1 2026 at Zenas BioPharma, up from $7.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.2 million in Q1 2026 to a low of $947000.0 in Q1 2024.
• Historically, Share-based Compensation has averaged $4.4 million across 4 years, with a median of $5.4 million in 2025.
• Biggest YoY gain for Share-based Compensation was 468.74% in 2025; the steepest drop was 37.94% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $1.1 million in 2023, then jumped by 384.14% to $5.5 million in 2024, then soared by 37.94% to $7.6 million in 2025, then climbed by 21.31% to $9.2 million in 2026.
• The last three Share-based Compensation figures came in at $9.2 million (Q1 2026), $7.6 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.